SIK Inhibitors
Salt-inducible kinases (SIKs), comprising three isoforms (SIK1, SIK2, and SIK3), are members of the adenosine monophosphate-activated protein kinase (AMPK) family. Originally identified in the adrenal glands of salt-loaded rats, SIKs are now recognized as pivotal regulators of metabolism, inflammation, and cellular homeostasis. The activity of SIKs is primarily regulated by the upstream kinase LKB1, which phosphorylates the T-loop of the SIK catalytic domain, and by cyclic AMP (cAMP) signaling, which leads to SIK phosphorylation by protein kinase A (PKA) and subsequent inactivation. SIKs exert their biological effects by phosphorylating specific substrates, most notably the CREB-regulated transcription coactivators (CRTCs) and class IIa histone deacetylases (HDACs). When SIKs are active, they phosphorylate CRTCs and class IIa HDACs, sequestering them in the cytoplasm. Upon SIK inhibition or inactivation, these proteins translocate to the nucleus, where CRTCs enhance CREB-mediated transcription and HDACs modulate the expression of various genes involved in gluconeogenesis and inflammation. The therapeutic potential of SIK inhibitors is being explored across several disease domains.
In immunology, SIK inhibition has been shown to promote an anti-inflammatory phenotype in macrophages and dendritic cells by increasing the production of interleukin-10 (IL-10) and decreasing pro-inflammatory cytokines like TNF-alpha and IL-12. This makes SIK inhibitors attractive candidates for treating autoimmune and inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease. In oncology, SIK2 is frequently overexpressed in ovarian cancer and is involved in centrosome separation and mitotic progression, suggesting that its inhibition could impair tumor cell division. Furthermore, SIK3 has been identified as a potential target in acute myeloid leukemia (AML). Another interesting application is in dermatology; SIK inhibitors can induce melanogenesis (skin tanning) by upregulating the expression of MITF and tyrosinase, offering a potential strategy for UV-independent skin protection and treating pigmentation disorders. Currently, several small-molecule SIK inhibitors have been developed, although many are multi-kinase inhibitors with significant off-target activity. For example, the FDA-approved leukemia drug dasatinib is a potent pan-SIK inhibitor, and much of its anti-inflammatory effect is attributed to this activity.
More selective tool compounds, such as HG-9-91-01 and YKL-05-099, have been developed to better define the roles of individual SIK isoforms in preclinical studies. These inhibitors are generally ATP-competitive. The field is currently focused on improving the selectivity and pharmacokinetic properties of these compounds to enable clinical translation. One of the primary challenges in developing SIK inhibitors is the high degree of structural similarity between the three isoforms and other AMPK family members. Additionally, because SIKs play diverse roles in glucose and lipid metabolism, systemic inhibition may lead to metabolic side effects. Future research aims to develop isoform-specific inhibitors and explore tissue-targeted delivery systems to maximize therapeutic efficacy while minimizing potential toxicity. Combination therapies, particularly in the context of cancer and immunotherapy, are also an area of active investigation.